Loading clinical trials...

Cannabidiol for the Treatment of Pelvic Pain in Endometriosis (DREAMLAND) | Clinical Trials | Clareo Health

TERMINATEDPHASE2/PHASE3

Cannabidiol for the Treatment of Pelvic Pain in Endometriosis (DREAMLAND)

Cannabidiol in the Treatment of Women With Chronic Pelvic Pain Secondary to Endometriosis

NCT05670353•University of Sao Paulo

Summary

The objective of this work is to conduct a randomized, double-blind, placebo-controlled clinical trial to assess the efficacy and safety of cannabis extract in women with endometriosis who have already undergone hormonal contraceptive treatment and surgery without satisfactory response.

Detailed Description

The Dreamland study is a two-arm, parallel-group, individually randomized (1:1 allocation ratio), controlled by disease stage, participant and investigator blinded, single-site superiority trial of oral cannabis extract (CBD). CBD will be given orally starting at 10 mg daily and up-titrated to a maximum dose of 150 mg daily. Dose up-titration will be based on clinical response or side effects, whichever comes first. After 63 days of treatment, gradual withdrawal will be performed during one week. Then, at 70 days, there will be an open-label extension wherein all participants from control group will be offered a course of CBD according to the same previous protocol. This research intends to : 1. Assess whether the daily use of CBD, for nine weeks, will reduce the pain level of these women. 2. Assess whether the daily use of CBD, for nine weeks, will modify pain threshold. 3. Assess whether the daily use of CBD, for nine weeks, will interfere in psychological symptoms. 4. Assess the possible adverse effects of using CBD

Eligibility

Age

18 - No limit years

Sex

FEMALE

Healthy Volunteers

Inclusion Criteria

•Women with chronic pelvic pain secondary to endometriosis surgically treated, with refractory symptoms, and who are taking complementary hormone therapy;
•Women over 18 years of age who wish to participate in the clinical trial;
•Willingness to voluntarily participate in the study to accept randomization to either of the two treatment arms;
•Participating exclusively in this clinical trial during the study period;
•Possess a telephone (cell or landline) that may be available to receive daily calls throughout the study period;
•Signature of the Free and Informed Consent Term (TCLE) approved by the Local Research Ethics Committee.

Exclusion Criteria

•Chronic, severe or uncompensated medical conditions, such as: insulin-dependent diabetes (types 1 or 2); uncontrolled high blood pressure, lung disease such as asthma or other chronic obstructive pulmonary disease; hematological diseases, liver diseases, chronic kidney disease in advanced stage (grade 3, 4 and 5), metabolic disturbances and immunosuppression;
•Use of any medication with potential interaction with CBD/THC (such as chloroquine, clobazan, warfarin, or valproic acid) or history of undesirable reactions prior to the use of this medications;
•Inability to use oral medication;
•Pregnancy or lactation;
•History of alcohol or drug addiction;
•Smoking in the last three years;
•Marijuana use in the past three months or a lifetime history of dependence;
•Inability to cooperate with investigators due to cognitive impairment or mental status.

Locations (1)

Center of Chronic Pelvic Pain and Gynecologic Endoscopy of Ribeirao Preto Medical School, University of Sao Paulo

Ribeirão Preto, São Paulo, Brazil

Key Dates

Start Date

January 3, 2023

Primary Completion Date

September 12, 2024

Completion Date

November 20, 2024

Last Updated

April 2, 2025

Enrollment

ACTUAL participants

Conditions

EndometriosisPelvic Pain

Interventions

Cannabis Derivatives

DRUG

Placebo

DRUG

Hormonal Contraceptive Agents

DRUG

Trial of Ovarian Vein and Pelvic Vein Embolization in Women With Chronic Pelvic Pain and Pelvic Varices

NCT06168058

Chronic Pelvic Pain SyndromePelvic Pain+3 more

View study

RECRUITING

The Developmental Origins of Endometriosis

NCT05951452

Endometriosis

View study

RECRUITING

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 2, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Cannabidiol for the Treatment of Pelvic Pain in Endometriosis (DREAMLAND)

Inclusion Criteria

Exclusion Criteria

Trial of Ovarian Vein and Pelvic Vein Embolization in Women With Chronic Pelvic Pain and Pelvic Varices

The Developmental Origins of Endometriosis

Glycemic Regulation as Endometriosis Adjunct Treatment

The Role of Preoperative Immunonutrition on Morbidity and Immune Response After Cystectomy (INCyst Trial)

Effect of Tele-Yoga on Pain, Fatigue, and Quality of Life in Endometriosis

Comparison of Proton or Intensity Modulated Radiation Therapy After Surgery for Endometrial or Cervical Cancer